Mavenir Launches Open RAN Intelligent Controller (O-RIC) Offering Enabling Service Differentiation and Network Resource Optimization
10.2.2023 17:00:00 EET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announced the availability of its O-RAN alliance Radio Access Network Intelligent Controller (RIC), a next-generation network intelligence offering for Open RAN. Mavenir O-RIC enables the creation of differentiated services through open APIs, which enable intelligent closed-loop end-to-end network tuning to optimize network performance, increase cost efficiency and maximize the user experience. Mavenir’s O-RIC offers Network Intelligence as a Service (NIaaS) that provides deep, fine-grained insights about the network and enables building solutions with advanced state of art intelligence. Open RAN networks can also now generate new class-of-service revenue streams by adaptively reacting in near-real time to dynamic changes in network, traffic, and load patterns. Mavenir’s O-RIC is currently in deployment with two, tier one Communications Service Providers (CSPs).
Traditional RAN networks currently use area wide Self-Organizing Network (SON) models for exercising Radio Resource Management (RRM) and configuration management optimization decisions at a per-cell level. They rely on single control loop, leverage key performance indicators (KPIs) and analytics for such control decisions at non-real time (Non-RT) granularities.
Mavenir’s O-RIC surpasses the capabilities of SON with two control loops:
- Non-RT O-RIC — Typically deployed in a centralized cloud, it builds advanced Machine Learning (ML) algorithms using long-term RAN data to define dynamic and adaptive policies to control and optimize network performance and configuration management decisions. Non-RT RIC can also be used in existing legacy networks, adding another performance layer through ML for policy control.
- Near-real time (Near-RT) O-RIC — Deployed at or towards the edge, it uses a low latency control loop that optimizes RAN activity at both the cell and individual user equipment (UE) level by hosting trained Artificial Intelligence (AI) and ML applications to infer and control Open RAN elements in near-RT. The near-RT O-RIC intelligently optimizes UE-level control-plane call processing and user-plane data transfer decisions. This level of granularity is not available in SON.
Mavenir’s O-RIC is a business results tool, that enables intent-based decisions by setting granular performance targets—at the cell or even individual UE level—to generate business outcomes, such as the generation of additional revenue (enabling an SLA that generates a premium service), the reduction in network cost through the optimization of resources (energy savings, spectral efficiency, etc.), or the improvement of the end user experience (by improving throughput, reducing latency and connection drops, and expanding coverage). The NIaaS signature framework of Mavenir’s RIC accomplishes this goal by offering fine-grained predictive intelligence and advanced analytics about the RAN to third party applications (rApps and xApps), integrated with Mavenir’s O-RIC, towards optimizing the network performance.
Mavenir’s O-RIC shifts control from the vendor ecosystem to the operator by delivering an Open API framework that allows the implementation of standards-based rApps and xApps for different business outcomes, such as energy savings, traffic steering, massive MIMO optimization, spectral efficiency improvements, and RAN slice assurance. Proprietary radio access solutions limit the choice to what their vendor has to offer and open up the network to fine-grained per user data-driven optimization. With Mavenir’s RIC, applications can be developed by an in-house team or purchased in an "app store" from any Open RAN compliant third party.
"Creating real business value for next-generation Open RAN networks requires deep telco domain expertise and a disruptive approach to network intelligence," said Brandon Larson, SVP & GM of the Multimedia Business Unit at Mavenir. "As a pioneer in cloud-native solutions at a massive scale, Mavenir is leading the way with award-winning Open vRAN solutions, layered with O-RIC AI and ML algorithms and applications, which create operator customizable business outcomes based on target objectives to solve unique business problems and give control of the network back to the CSP."
Mavenir's O-RIC offers unparalleled benefits in terms of (i) Network performance, (ii) User Experience, (iii) Reduced TCO, (iv) Simplified cloud-native deployments, (v) new revenue sources, etc.
For more information visit the Mavenir Open RAN Intelligent Controller page.
Mavenir is exhibiting at Mobile World Congress 2023 in Barcelona, Spain at the Fira Gran Via in Hall 2, stand 2H60. Click here to find out more.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005022/en/
Contact information
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
